Since a Swiss physician first recorded the phenomenon in 1609, only a hundred men across all of human history have been documented as born with two penises — a condition so rare it touches perhaps one in five million lives, and so singular that a recent birth in Iraq, involving three, stands alone in all of medical record. Diphallia reminds us that the body's formation is a process of extraordinary precision, and that when that process is disrupted, the consequences reach far beyond anatomy into identity, belonging, and the long work of living with difference. Medicine has learned to intervene
Diphallia: The Rare Condition of Men Born With Two Penises
Related Coverage
Cuba conmemora 21 años del Contingente Internacional de Médicos Henry Reeve, creado en 2005 tras el rechazo estadouniden…
Prensa Latina · Sep 19 Foro regional en Etiopía prepara al Cuerno de África para intenso episodio de El NiñoLa IGAD convocó un foro de alto nivel del 15 al 17 de septiembre en Addis Abeba para coordinar medidas de preparación an…
La Vanguardia · Sep 19 El 'hacker de Hollywood': "Con la IA, cualquiera puede ser un pirata informático"Ralph Echemendia, experto en ciberseguridad conocido como 'hacker de Hollywood', advierte que la inteligencia artificial…
RRHH Digital · Sep 19 Síndrome de Diógenes digital: cómo la acumulación de datos inútiles cuesta dinero a las empresasLas empresas acumulan masivamente datos inútiles (Dark Data) que generan costes invisibles, vulnerabilidades de segurida…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
This article discusses diphallia, a rare medical condition, with no geopolitical implications.
Economic Lens
Article discusses diphallia, an extremely rare congenital condition affecting ~1 in 5-6 million births with only 100 documented cases. No direct economic implications identified.
Minimal. Affects extremely small patient population (~100 cases globally). Patients may face increased healthcare costs for specialized surgical interventions and urological care, but aggregate market impact is negligible.
No significant policy implications. Medical treatment protocols already established through standard urological surgical practices. Potential minor impact on rare disease research funding allocation.